Skip to main content

Opaleye Management Inc.'s Form 4/A amendment

Amended

Eton Pharmaceuticals, Inc.ETON · filed Jul 17, 2026

Accession no.
0001493152-26-033818
Filed
Jul 17, 2026, 7:12 PM ET
Trade date
Jul 14, 2026
Filing delay
3 days
Rule 10b5-1 plan
Not checked
Original filed
Jul 16, 2026

This filing lists 2 non-derivative transactions. Open-market sales total $1.06M. It was filed 3 days after the trade.

This amendment replaces 0001493152-26-033577 (filed Jul 16, 2026).

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Opaleye Management Inc.CIK 000159585510% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jul 14, 2026Common Stock, par value $0.001 per shareSSaleDisposed−15,000$37.54F3−$563,146.52,665,000Indirect
Jul 14, 2026Common Stock, par value $0.001 per shareSSaleDisposed−13,315$37.54F3−$499,886.3840,000Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

Represents securities owned directly by Opaleye, L.P. (the "Fund"). As the investment manager of the Fund, Opaleye Management, Inc. may be deemed to beneficially own the securities owned directly by the Fund.

F2

Securities owned by a separately managed account (the "Managed Account"). As the portfolio manager of the Managed Account, Opaleye Management, Inc. may be deemed to beneficially own the securities owned directly by the Managed Account.

F3

The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.0152 to $37.9148 inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each price.

Referenced by the price of 2 transactions in Table I.

F4

Opaleye Management, Inc. disclaims beneficial ownership of the shares reported herein except to the extent of its pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that Opaleye Management, Inc. is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Remarks

This amendment is filed solely to check the box indicating that the reporting person is no longer subject to Section 16.

Read the full filing on SEC EDGAR (opens in a new tab)